The Michigan Medicine pilot study was designed to fill this gap by providing a direct comparison between the two dietary approaches. In this randomized controlled trial—the first of its kind to compare the Mediterranean diet to another active dietary intervention for IBS—researchers recruited patients diagnosed with either IBS-D or IBS-M. These participants were randomized into two distinct groups. For a period of four weeks, one group followed the Mediterranean diet, while the other followed the traditional restriction phase of the low FODMAP diet.
To measure success, the researchers utilized an FDA-standard primary endpoint: a 30% reduction in abdominal pain intensity after the four-week period. This metric is considered a rigorous benchmark for determining whether a treatment provides clinically meaningful relief to the patient. Additionally, the study monitored overall IBS symptom severity scores to capture a broader picture of the patients’ daily experiences.
The results of the pilot study offered an encouraging look at the potential of the Mediterranean diet. In the group following the Mediterranean pattern, 73% of the patients met the primary endpoint for symptom improvement. While the low FODMAP group saw a slightly higher success rate, with 81.8% of patients meeting the endpoint, the gap was narrow enough to suggest that the Mediterranean diet is a powerful contender in the realm of gastrointestinal health. While the low FODMAP group did experience a greater overall improvement in both abdominal pain intensity and IBS symptom severity scores, the high response rate in the Mediterranean group highlights its potential as a more accessible and sustainable starting point for many patients.
The significance of these findings lies in the concept of accessibility. The Michigan Medicine team has a history of investigating ways to make IBS management less daunting for the average person. Previous investigations led the researchers to propose a "FODMAP simple" approach, which attempted to restrict only those specific food groups within the FODMAP acronym that were most likely to trigger symptoms in a particular individual. The move toward testing the Mediterranean diet is a natural extension of this philosophy—seeking a balance between clinical efficacy and the practical realities of a patient’s life.
Dr. Singh emphasized that the Mediterranean diet overcomes several of the most pressing limitations associated with more restrictive protocols. Because it does not require the strict elimination of entire food categories, the risk of nutrient deficiency is significantly lower, and the social and psychological burden of the diet is greatly reduced. For a patient who may already be struggling with the anxiety that often accompanies chronic GI issues, having a "menu" of options that includes a diverse and flavorful diet like the Mediterranean one can be a major boost to their quality of life.
